BAT’s June Gauntlet: EU Consultation Deadline and Half-Year Update Raise Stakes

British American Tobacco steps into the spotlight today with a pre-close trading update that could either reaffirm its 2026 targets or force a rethink. But the numbers are only half the story. A parallel regulatory battle in Brussels — where the European Commission’s review of the Tobacco Product Directive is drawing to a close — threatens to reshape the market for the company’s most promising growth engine: smoke-free products.

The public consultation on the directive’s revision runs until 15 June, and BAT has launched a pan-European campaign called “Share Your Voice” to mobilise adult consumers and trade partners against potential bans on next-generation nicotine products. The Commission’s April evaluation signalled that tighter controls — including outright prohibitions in some categories — could be on the table. Legislative proposals are expected before the end of the year.

BAT argues that intelligent regulation can improve public health without jeopardising a sector that generates more than €107 billion in annual tax revenue and supports nearly 1.45 million jobs across Europe. More than 30 million European adults have already switched from combustible cigarettes to smoke-free alternatives, the company notes, and they deserve to weigh in before any restrictions are imposed.

A Cross-Border Regulatory Squeeze

The EU is not the only front. In the UK, parliament has passed an anti-tobacco law that will permanently ban the sale of tobacco products, e-cigarettes and heated tobacco to anyone born after 2009. The measure effectively phases in a total prohibition, raising the minimum purchase age by one year every year. For a company that still derives the bulk of its revenue from combustible cigarettes, the twin regulatory pressures underscore the urgency of its transformation strategy.

Should investors sell immediately? Or is it worth buying British American Tobacco?

That transformation took centre stage in today’s trading update, released at 7am UK time, with an analyst call led by CEO Tadeu Marroco, interim CFO Javed Iqbal and investor relations chief Victoria Buxton at 8:30am. For 2026, BAT is targeting revenue growth of 3% to 5% and adjusted operating profit growth of 4% to 6% — both at the lower end of its medium-term ambitions. Those goals were already framed as cautious at the start of the year, and the headwinds have only intensified since.

The Iran conflict has added geopolitical uncertainty, while the duty-free channel and traditional cigarette volumes continue to weaken. Investors are looking for clarity on whether pricing power and new-category sales can offset the drag. The company has previously flagged that profitability improvements would be back-end loaded to the second half, so today’s update will be measured more by management’s tone than by any single number.

Smokeless Momentum Buoys the Narrative

Still, the smokeless segment is delivering. In the most recent quarterly report, revenue from next-generation products rose 17% on a constant-currency basis. Vuse, the vaping brand, saw volumes climb 12%, while Velo’s nicotine pouch volumes jumped 28%. At the end of 2025, 31 million adult consumers globally were using BAT’s smoke-free brands — Vuse, glo and Velo — many as a complete substitute for cigarettes.

The company aims to reach 50 million users by 2030 and to have smoke-free products account for half of group revenue by 2035. Those targets are ambitious but essential if BAT is to offset the structural decline in combustibles. Alongside the product shift, the group is also building a digital hub in Bengaluru that will centralise cybersecurity, data analytics, artificial intelligence and digital platforms — though that initiative is a longer-term play.

Stock Price: Overbought but Slipping

On the market, BAT’s shares have been a story of two speeds. At around €53.02 this morning (up 0.68% on the day), the stock has gained nearly 34% over the past 12 months and roughly 10% year-to-date. Yet the recent seven-day stretch tells a different tale: a 5.67% decline that has dented short-term momentum. The relative-strength index sits at 98.6, signalling extreme overbought conditions — a technical warning that a pullback may be overdue.

British American Tobacco at a turning point? This analysis reveals what investors need to know now.

What keeps investors anchored are the dividend yield, which remains above 5%, and an ongoing share buyback programme. The company is also expected to provide an update on net debt, which it aims to keep within a range of 2.0 to 2.5 times EBITDA. A clear reaffirmation of all targets today would reinforce the recovery narrative; any hedging on duty-free or cigarette volumes would validate the recent sell-off.

With the EU consultation still open for another 13 days and a legislative timetable that runs through year-end, BAT is navigating two overlapping catalysts. How convincingly management addresses both — the immediate financials and the longer-term regulatory landscape — will set the tone for the rest of 2026.

Ad

British American Tobacco Stock: New Analysis - 2 June

Fresh British American Tobacco information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated British American Tobacco analysis...

en | GB0002875804 | BAT’S | boerse | 69467358 |